Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop  SARASOTA, FLA., Aug.  10, 2026  (GLOBE NEWSWIRE) --  Silo Pharma

SILO

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

SILO secures European patent for SPC-15 PTSD prevention, expanding IP moat

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop  SARASOTA, FLA., Aug.  10, 2026  (GLOBE NEWSWIRE) --  Silo Pharma</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Silo Pharma announced that the European Patent Office granted EP3952852 for SPC-15&#039;s preventive, nose-to-brain approach to PTSD, reinforcing an IP moat and global development rights under an exclusive license with Columbia University. The patent cites prophylactic efficacy of 5-HT4 receptor agonists and could support European commercialization partnerships and broaden SPC-15&#039;s risk-adjusted value.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>European patent granted for SPC-15 PTSD prophylaxis. Strengthens IP moat and EU reach.</li><li>EP3952852 covers prophylactic efficacy against stress via 5-HT4 agonists.</li><li>Silo holds exclusive European license with Columbia University for SPC-15.</li><li>Preventive approach could shift PTSD care paradigm, per CEO.</li><li>EU patent complements five other major global markets.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Silo Pharma, Inc. (SILO)</strong>: Patent grant strengthens SPC-15 IP moat; exclusive license with Columbia University.</li><li><strong>Columbia University (N/A)</strong>: Exclusive global licensee for SPC-15; collaboration underpinning development and commercialization.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Corporate Developments: The patent grant and exclusive licensing arrangement reflect strategic IP expansion and potential global partnerships, aligning with SILO&#039;s broader pipeline strategy and reinforcing its high-uncertainty, high-upside value proposition.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>EP grant strengthens SPC-15 IP, potentially catalyzing licensing discussions.</li><li>Exclusive Columbia license underscores collaboration value and global rights.</li><li>SPC-15 remains pre-revenue; valuation hinges on milestones.</li><li>EU market expansion may attract partnerships and investor interest.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>European Patent No. EP3952852 granted.</li><li>Patent covers Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress.</li><li>SPC-15 is an intranasal nose-to-brain PTSD candidate.</li><li>Exclusive license for SPC-15 with Columbia University.</li><li>Press release date: Aug 10, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term: IP moat expansion could modestly lift SILO valuation as partnerships emerge.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center"><b><i>Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop</i></b></p>  <p>SARASOTA, FLA., Aug.  10, 2026  (GLOBE NEWSWIRE) --  Silo Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SILO">SILO</a>) ("Silo" or "the Company"), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the European Patent Office (EPO) has granted a patent covering the preventative approach of its lead candidate SPC-15, a novel intranasal, nose-to-brain treatment targeting post-traumatic stress disorder (PTSD) and stress-induced affective disorders. The Company has an exclusive license for the European patent from Columbia University.</p>  <p>The granted patent, European Patent No. EP3952852, "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," covers methods of preventing stress-induced fear, depressive-like behavior and associated affective disorders by administering selected serotonin 4 (5-HT4) receptor agonists ahead of a stressor such as potential extreme stress exposure.</p>  <p>"We continue to strengthen the powerful intellectual property moat around SPC-15’s technology—a differentiated approach to PTSD treatment that targets pathways associated with stress resilience rather than relying solely on symptom management after PTSD has developed," said Eric Weisblum, Chief Executive Officer of Silo Pharma. "We are pleased with the EPO’s decision recognizing the novelty of this preventative approach and extending important patent protection for SPC-15 in the European market. We believe the ability to intervene before exposure to acute trauma could represent an entirely new paradigm for protecting individuals at high risk of developing PTSD and other stress-related disorders."</p>  <p>The new European patent further expands the intellectual property portfolio supporting SPC-15 and complements patent protection granted and pending in five other major global markets.</p>  <p>Silo holds an exclusive license agreement with Columbia University to further develop, manufacture, and commercialize SPC-15 globally.</p>  <p><b>About Silo Pharma, Inc.</b></p>  <p><b>QwikAgents</b>, Silo Pharma&#39;s wholly owned artificial intelligence subsidiary, is a managed AI agent platform that delivers dedicated autonomous agents for research, content generation, scheduling, and workflow automation — each running in a persistent environment with proprietary smart-routing across multiple AI models. The subsidiary reflects Silo&#39;s strategy to expand into high-growth technology markets while continuing to advance its core biopharmaceutical pipeline. <a href="https://www.globenewswire.com/Tracker?data=1DdFiXEWGl8pgXiATtjfyKQ0IjjwHaMjZPiZmWs6TmOQUOmlYo3QEKaOIXAmNqF6ObVzk77xBkkWp7BEj_aZz9KrYWWmacJak-mDKSQZorzJr33FrxLulcmNjUy71BbbgcuWTR-8eVwFblhGmVTWqqs_hvWm2LtUWc854TJTQwDbt3_NRmnC6O0uuVzbQ9vMgbl479zU78YomyUXmrS4bF9h2tuEBeIfFTJg8tn3Z80=" rel="nofollow" target="_blank">qwikagents.com</a></p>  <p><b>Silo Pharma</b> is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. <a href="https://www.globenewswire.com/Tracker?data=gm94fgbL41QIsPKIgtO8ohixriMDCk_MgX3Vh3OVJuDI0yqPtwB6HG4_rg2d6LruHe8T9XB4Ucjyv18dT-0H4tvvL69YUTE6AvlKK3ZZVIn2X9K3pId64MQnwJ3OtdCV6ZP9o40XJBN3wLoMOQep1Jd6IFEFioIoKPtsMs4L5pGmIvvw3IStoHpJlHjTwiYsF-9oDCEoC69Cg5CR-3rj-B4tCK0SsPa1byJKxAjFOnldX-DxKuCSweDz13Ix7EulZwVVlqQEDAjMa6_03Mbynt6bHr5rYOv93AU1vNG5-20zjwDniZklDPssHNtEq4nVQX0HNAgyu1bK7PxUjngvXTAGEGFJQZCEQIOFxlRtrE0S1WcqcLA_sUSx9hFhG8SkQmmeYY9lfiiM8XFCgcO9UI5nFmOEjARhCkWCII7AKhLvycckKSuwjnDAwR4DdobK1yUzS1fN7RCQw3YgdQLFUz6H2KfcSrtqfPxA_U5f3Y15Mp4Vvb0rSp52ev21-tvN5iOBnT1I7u5yw75BjyRlX2wEWUFK01VIrqj_bXSsZdTFv0Kn7XdvGQF0nM5M285Q6S19QeKpxsOtwuiL54PMVgFX3flCYfoqsK_A4UXyaUQu106iTzC55UY8XNouW60dmyH_BiIleqaGYGCWI8Qrgsi3FnP3iZOYydGMXnhRH2yZmgKXTf63uyv-xn60sh3Xe2wEzWBgJhKKiJobJn4kJJ3gYyHv6gLNqRYzCDf7EhO9DN_PgTH2NzfPNODvLr0TU6zbwMT1CHHB98LdhULitIergGLafFJNbe1AK34-JtH1fckkQkAR8xf9_1oE3rkMH2cAbxVFMGfrwxKzm0Me2YwsMsG2grxDk9YG0lcoHgwCNAkvhyXzH2aJoUs6TDoxDMU4O0_HCjsAkQAZ9rzDkwj11Ct3ZGSWn8-GVH_uAnMVI06nohjoZhCh21GPyBXa6N3PlOtk-TYaX2JYIYu88VMJk06LWBcIQIg2vSW6-C-vY3rq4s4XLmC73nuCDNZm" rel="nofollow" target="_blank">silopharma.com</a></p>  <p><b>Forward Looking Statements</b></p>  <p>This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential", and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.</p>  <p><b>Contact</b></p>  <p>(800) 705-0120<br></br><a href="https://www.globenewswire.com/Tracker?data=HMHj0WlqaWu326xlY4qjRg-qd60YaQlAQCs6_aW_aDipXqjVzp9OSbtYa6ZLaxbs_Nd3Bk7PegImKC-IREX7C9-ApzUvc48JTScLFZd0w1y9xDlDhUMDBxrYg9sTiohn9EapmhbBNyQOHclwpMtDef75q0EylGtrSRsiYWnOICYQj-itgIKAqfn_4c4hb9vIkENJfHUC1lCtt08dmVLYZj36AGWrMC7CUzWKrFnek4JqDGmDJ9xcMD6HUNesOtps0SIsLTS_zs6l20F2gdhhHhxKWcz5q749Z0poCFDJp5py4ERPzq771yluTMvJNt0ZXOmJeM_Vj-AG-jkluVqVraXAs_NdQWYtiBRoddRttAq6wiFO-wE24y0Z0b1gt6DyGqfqrJjEfyR9USvUtAdfEJor-kDuzVqTs7Wab6PSfVt7psUQjbrlCOEZ1H3K4Xbdw-60VB26cK62mF3qVaCKEx2MZIid4qv8FUZlNmDuABNlNGLF4LCmW1Uhf_ItODNFLaz_4qPgVeyRKVN2k8WxaA==" rel="nofollow" target="_blank">investors@silopharma.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwNjYyMiM3NzY3MDUxIzUwMDA2OTMzOQ=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NmViNTlmMjgtZTg4Ny00NzA3LWJhMjQtMTI0OTlhZDg4OTYzLTUwMDA2OTMzOS0yMDI2LTA4LTEwLWVu/tiny/Silo-Pharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b635464-4382-4b8b-8175-39cc32e08050"><img src="https://ml.globenewswire.com/media/3b635464-4382-4b8b-8175-39cc32e08050/small/logo-png.png" border="0" width="150" height="73" alt="Primary Logo"></img></a></p>

Silo Pharma announced that the European Patent Office granted EP3952852 for SPC-15's preventive, nose-to-brain approach to PTSD, reinforcing an IP moat and global development rights under an exclusive license with Columbia University. The patent cites prophylactic efficacy of 5-HT4 receptor agonists and could support European commercialization partnerships and broaden SPC-15's risk-adjusted value.

News insight

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

AI summary

Sentiment rationale

Key facts

Corporate Developments